Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Hisse Senetlerindeki Sıralama #40845
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Hisse Fiyatı
$0.00884456
Piyasa Değeri
$73.61K
Değişim (1 gün)
-3.70%
Değişim (1 yıl)
32.93%
Ülke
GB
Ticaret Thalia Therapeutics Plc (THAT)

Kategori

Thalia Therapeutics Plc (THAT) için P/B oranı
2026 itibarıyla P/B oranı TTM: 0
Thalia Therapeutics Plc şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/B oranı 0 idi.
Thalia Therapeutics Plc için P/B oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/B oranı
Yıl P/B Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/B oranı
Şirket P/B Oranı P/B Oranı Farkı Ülke
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE